Featured PodcastPodcast Highlights

New Developments in Tetracycline-Class Antibiotics

By December 21, 2020March 18th, 2021No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

New Developments in Tetracycline-class Antibiotics

Dr. Christopher Bunick & Dr. Adam Friedman


Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline.

 Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).

Listen Now
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.



Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

You May Also Like

Heal the Burn: Radical Updates for the Management of Radiation Dermatitis

| Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Beth N. McLellan, MD & Adam Friedman, MD, FAAD   All of those wonderful life saving toys the radiation oncologists get to play with come…

Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved

| Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Mario E. Lacouture, MD & Adam Friedman, MD, FAAD   While the old adage, "more oncology treatments, more skin problems," becomes more like dogma every…

AD Treatment – The Future Landscape

| Atopic Dermatitis, Featured Podcast, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Drs. Amy Paller, Jonathan Silverberg & Adam Friedman   Consider this final episode of the 5 part all you can handle Atopic Dermatitis series the…

Leave a Reply